Disease (GvHD) after allogeneic stem cell transplantation, mainly because murine models suggest that adoptive transfer of these cells will not hamper the Graft versus Tumor (GvT) effect.
Introduction
Naturally occurring regulatory T-cells (Tregs) possess excellent capacities to suppress T cells mediating GvHD after allogeneic Stem Cell Transplantation (allo-SCT) and donor lymphocyte infusions (DLI) (1) (2) (3) (4) (5) (6) . Indeed, the first clinical trial showed the successful control of GvHD by coinfusion of CD4 + CD25 + Tregs, hereby encouraging the further clinical application of Tregs in this setting (6) . Nonetheless, when allo-SCT and DLI are applied as treatment of hematological cancers, a potential pitfall may be the suppression of the beneficial Graft-versus-Tumor (GvT) effects. Although some murine studies demonstrated the maintenance of the GvT effect after co-infusion of Tregs with effector T cells (7, 8 ) the impact of human Treg infusions on GvT remains largely unexplored (6) . In particular, it is unknown whether Tregs will permit GvT against different types of hematological tumors, with different immunogenicities, growth patterns and locations. Furthermore, it needs to be clarified why Tregs allow GvT in the allo-SCT setting (7, 8) , whereas they seriously impair the antitumor immunity in several models for solid tumors (9) (10) (11) (12) (13) (14) (15) . Toward application of human Tregs in clinical trials, we were prompted to gain thorough insight in tumor-related conditions, such as tumor immunogenicity and tumor location, which might influence the effect of Tregs on GvT. To address this, we applied a humanized GvT model, in which infusion of human PBMC in immune deficient RAG2 -/-γc -/-mice carrying human tumors induces a T-cell-mediated GvT effect, but also lethal xenogeneic(x) GvHD (16, 17) . Previously, we have optimized this model to accommodate various multiple myeloma (MM) tumors with different immunogenicities growth rates and growth locations, i.e. either primarily inside or outside the bone marrow (BM) (16) . Furthermore, we have shown that freshly isolated human Tregs can effectively control the development of xGvHD in this model (1) .
Although there are many differences between xGvHD and human allo GvHD, the successful control of We demonstrate that fully functional ex vivo cultured human Tregs -as evident by suppression of xGvHD-, do not suppress the GvT effect against MM tumors that reside within the BM, largely independent of their immunogenicity or growth rates. However, human Tregs readily inhibited the GvT effect against tumors residing outside the BM. Further exploration provided evidence that this remarkable phenomenon may be due to the capacity of BM to neutralize the suppressive activity of Tregs, in part by converting them into interleukin-17 (IL-17)-producing T cells.
Research. 
Materials and methods

Isolation of human BM cells, blood cells, and expansion of human Tregs
Human PBMCs (huPBMCs) for isolation of Tregs, in vitro suppression assays and infusion into mice were isolated from healthy donors by Ficoll density gradient centrifugation (16) 120 U/ml IL-2 (Proleukin) and 100 mg/ml kanamycin (Invitrogen) for 10-14 days. At the start of culture 5ng/ml recombinant TGF-β1 (Peprotech) was added to stabilize expression of FOXP3 and suppressive function (19) . Using this protocol, Tregs expanded more than 100-fold after one round of antibody (eBioscience) and recombinant human IL-1receptor antagonist (IL-1RA) (R&D systems) as described elsewhere (21) .
In vitro analysis of Treg function
In vitro suppression of T-cell proliferation by Tregs was tested either in standard 3 
Induction and monitoring of GvT and xGvHD
The inoculation of RAG2 -/-γc -/-mice with Luciferase-transduced tumor cells, induction of GvT and xGvHD by injection with human PBMC and monitoring of xGvHD were carried out as described in previous studies (7, 16, 17) . BLI was used to quantitatively monitor tumor progression of tumor load inside and outside the BM as has been described in detail previously (16, 23 
Phenotype analysis of Tregs after co-culturing with BM stromal cells and MM cells
After 
Statistical analyses
Univariate-and survival analyses of in vivo experiments were executed with GraphPad Prism (version 4.0) and significance of differences were tested with Mann-Whitney U or log-rank tests. Data on paralysis, T-cell counts and in vitro T-cell function and -phenotype were analyzed with a two-tailed ttest (GraphPad Prism). P<0.05 was considered significant.
Research. T-cell responses against less immunogenic antigens are more prone to suppression by Tregs (24) .
Therefore, in the same experiment setting we also questioned whether human Tregs would abrogate
GvT against a less immunogenic tumor, derived from human MM cell line RPMI-8226, which also grow primarily in the BM (16) . As expected, we observed a less prominent GvT effect against RPMItumors (16). Co-infusion of human Tregs had only a slight but not a significant inhibitory effect on GvT ( Figure 2B ). These results, although not entirely ruling out the possibility, indicated that the immunogenicity of the tumor was not a major factor influencing the impact of Tregs on allogeneic
Research. GvT. Finally, when we used a murine BM tumor (A20 lymphoma) in similar settings, we observed that effector cells in human PBMC could also mediate a xenogeneic anti-tumor effect against these murine tumors (supplementary figure S2) . However, this anti-tumor effect was also not down regulated by Tregs, which were otherwise capable of reducing the xGvHD.
Tregs inhibit the GvT effect against tumors residing outside the BM
Human MM tumors U266 and RPMI as well as the murine A20 tumor exclusively grow in the BM in our model. Thus, to explore whether tumor location would influence the impact of Tregs on GvT, we used the MM cell line LME-1, which establishes aggressive tumors not only inside but also outside the BM (16) . Remarkably, we observed that the outcome of Treg-treatment depended on the tumor location: co-infusion of Tregs with PBMC resulted in significant outgrowth of tumors outside the BM ( Figure 3A, 3B) , while leaving the GvT effect against tumors residing inside the BM largely unaffected ( Figure 3A, 3C) . These results for the first time identified tumor location as an important factor influencing the clinical outcome of Treg treatment, and suggested that BM creates an environment preventing suppression by Tregs.
BM stroma converts Tregs into non-suppressor T-cells
Emerging evidence reveals that Tregs display plasticity to be converted into non-regulatory T-cells, mainly by pro-inflammatory cytokines IL-1β and IL-6 (21, (26) (27) (28) (29) . Since Tregs did not suppress GvT in the BM (Figures 2 and 3 producing cells is a property of both expanded and freshly isolated and unexpanded Tregs.
Since the in vitro assays suggested the conversion of Tregs into IL-17 producing non-suppressive cells in the BM microenvironment, we sought evidence for this in our LME-1 model, in which the GvT effect against extramedullary but not medullary tumors was abrogated. In a similar setting we treated the mice bearing LME-1 tumors with PBMC, PBMC+ Treg or no treatment. As expected, the Treg infusion controlled the xGvHD, reduced the CD4 + and CD8 + T cell numbers at week 3 but had a similar differential effect on GvT in the intra-and extramedullary sites (Supplementary figure S3) .
Hence we analyzed the conversion of Tregs into IL-17 producing cells within and outside the BM compartment ( figure 5 ). Since large extramedullary tumors did not allow the isolation of sufficient numbers of human T cells, spleen was analyzed as a site outside the BM. In addition, we have injected large numbers of effector PBMC+ Tregs in subcutaneously generated LME-1 tumors. In all analyzed mice, the fraction of FOXP3 + cells producing IL-17 was higher in the BM than in the spleen. propagation found in our humanized mouse model may also apply to the human situation.
Discussion
In this study we demonstrate that fully functional ex vivo cultured human Tregs can permit the T donor T cell mediated therapeutic anti-tumor effect against MM. However, the maintenance of the anti-tumor effect by Tregs appears a conditional phenomenon as it did not occur outside the BM.
Our analyses towards understanding the mechanism of this remarkable finding provide evidence that BM stromal cells can generate a microenvironment that neutralizes the suppressor activity of Tregs.
The neutralization of Tregs by BM stromal cells was in part due to the secretion of IL-1β and IL-6, which appeared to convert a fraction of Tregs into IL-17-producing cells.
Our findings may have important implications for the clinical application of human Tregs in the allo-SCT/DLI setting. First, by partly confirming the previous findings in murine models (7, 8) our results indeed encourage the co-infusion of naturally occurring Tregs in GvHD treatment. However, we now propose that Treg treatment will be appropriate and safe only in case of hematological malignancies progressing exclusively in the BM. This conclusion is supported by the distinct outcome of Treg administration on the GvT effect against LME-1 tumors growing in-and outside the BM. Actually, this novel finding of conditional regulation by Tregs in our model fits well with unexplained and apparently conflicting observations in previous studies. For instance, in several solid tumor models, where tumors usually reside outside the BM, Tregs were consistently shown to hamper anti-tumor immunity (9) (10) (11) 30) . In contrast, in murine allo-transplantation models, in which hematological tumors often reside in the BM, Tregs did not hamper the GvT effect (7, 8) . In fact, in some allotransplantation models GvT was abrogated when hematological tumors were put outside the BM (8, 12) . None of these studies, however, attributed a role for the BM environment in the clinical outcome, probably because they were not executed in a controlled manner (same tumor, inside and outside the BM at the same time) as we did. Now, our results combined with these previous observations, strongly suggest that BM microenvironment may contribute importantly to the outcome of Treg therapy. The mechanism of this may be the capacity the BM stromal cells to neutralize the suppressor function of Tregs. demonstrates that the loss of suppressive function in our in vitro cultures was not due to the outnumbering of FOXP3 + Tregs by residual FOXP3 -non-Tregs.
Our results may have specific implications for MM, which is a typical BM-residing tumor, but can also manifest at extramedullary sites. First of all, the treatment of MM by allogeneic transplantation and DLI is possible, but there is currently much reluctance to apply this mode of cellular immunotherapy due to severe toxicity related to GvHD. In the light of our results, we anticipate that MM patients with exclusively medullary tumors may significantly benefit from Treg therapy combined with DLI (3).
Here, an apparent controversial issue is the fact that, the IL-6 and IL-1β produced by BM stroma may also support growth of MM and are thought to induce resistance to conventional therapies (36) .
Furthermore, IL-17 producing T cells are also thought to promote MM growth (38) . However, our results suggests that these pathogenic effects may be effectively compensated by neutralization of
Tregs by providing an optimal platform for cytotoxic T cells to mediate the GvT effect.
Secondly, the differential Treg activity in medullary vs extramedullary sites may also help us to understand the mechanisms of extramedullary relapses, which comprises around 20% of all relapses after allo SCT (39) . However, since the majority of the patients display systemic relapses, and isolated extramedullar relapses occur only in a minority (2%) of the patients (39), it should be noted that differential Treg activity in medullary vs extramedullary sites is certainly not the main reason why relapse remains the most important cause of treatment failure.
Since in our model the neutralization of Tregs was mainly dependent on BM stromal cells, rather than the tumor itself, our results may be also relevant for other type of tumors residing in the BM. To assess the in vivo impact of bone marrow on IL-17 production by Tregs, T cells were isolated from BM or from spleen of LME-1 tumor carrying mice, which were treated with human PBMC alone or in combination with Treg (n=4) at day 14 of the treatment. To isolate sufficient number of T cells from extramedullar tumors, the effector cells and Tregs were injected into subcutaneously generated tumors in separate mice (n=6). IL-17 production in the FOXP3 + Treg fractions was analyzed. Error bars indicate SEM. *, ** p<0.05, and <0.005 respectively (unpaired t test)
.
Figure 6. Bone marrow propagates IL-17 in Tregs in clinical samples
IL-17 production in the FOXP3 + Treg fraction of multiple MM patients was analyzed in peripheral blood (PB; n=14), as extramedullary organ, and compared to bone marrow (BM; n=14). * p<0.05.
